UK Pharmaceutical Sector Braces for US Tariff Impact as Trump Escalates Trade Pressure

Trump's Pharmaceutical Tariff Order Takes Effect

US President Donald Trump ordered 100% tariffs on patented medicines entering the United States on Thursday, escalating his administration's trade war approach to the pharmaceutical sector^[1]. The White House announcement^[1] positions the levies as a national security measure designed to boost domestic medicine manufacturing.

The order does not affect generic medicines - the most commonly used medicines in the US^[1]. Companies can avoid the full tariff burden by committing to launch new manufacturing in the US before the end of Trump's term in January 2029, which would reduce their tariff rate to 20%^[1]. The rate drops to zero if firms strike pricing deals with the government^[1].

According to the CompanyPulse company register^[2], the UK currently hosts 5,683,615 registered companies as of April 2026, with 5,414,036 actively trading. The available data does not include pharmaceutical-specific company counts or sector breakdowns, limiting the ability to assess the direct impact on UK pharmaceutical manufacturers. The data shows other sectors such as real estate, management consultancy, and retail trade instead.

UK-US Pharmaceutical Trade Agreement Provides Protection

In December last year, the UK and US agreed a deal to keep tariffs on UK pharmaceutical shipments into America at zero^[1]. Under this agreement, the UK will pay more for medicines through the NHS in return for a guarantee that US import taxes on pharmaceuticals made in the UK will remain at zero for three years^[1].

On Thursday, the UK government called the partnership "a win for British patients, British businesses and the British economy"^[1]. The government stated that pharmaceutical companies would have "stronger incentives" to launch treatments in the UK, meaning patients would benefit from treatments such as new cancer therapies sooner^[1].

The US will also honour lower tariffs agreed as part of deals struck last year with key partners, including Europe, Switzerland, the UK, South Korea and Japan^[1]. This positions UK pharmaceutical manufacturers favourably compared to companies in countries without such agreements.

Broader Context of Trump's Trade War

The pharmaceutical tariffs represent the latest escalation in Trump's trade war, which began last April when he unveiled a minimum 10% tariff on many foreign goods^[3]. One year later, tariff rates in the US stand at the highest level in decades, with the average effective rate at roughly 10% up from about 2.5% at the start of last year^[3].

The impact on global trade has been substantial. The value of US imports from China plunged roughly 30% last year^[3]. By the end of last year, Chinese goods represented less than 10% of America's overall imports - comparable to levels last seen in 2000 and down from more than 20% in 2016^[3].

According to analysis by the BBC^[3], Trump's changes to the US tariff regime were more far-reaching than just his Liberation Day announcement. He also raised levies on specific items such as steel, lumber and cars and ended rules that had allowed shipments worth less than $800 to enter the country^[3].

Implementation Timeline and Company Response

A senior US administration official said big companies would have 120 days to work out agreements with the administration^[1]. Small and medium-sized companies will have 180 days^[1]. "They've had plenty of warning so we are going forward and executing," the official said^[1].

Sean Sullivan, professor at the University of Washington and London School of Economics, told the BBC: "The goal is to bring the rest of the companies to the bargaining table. It's all about leverage."^[1] Many of the biggest drug-makers have already struck agreements that will allow them to escape the levies, with more expected to do so in the weeks ahead^[1].

In previous agreements, companies have agreed to sell some of their medicines to government health insurance programmes such as Medicaid for prices comparable to those in certain overseas markets^[1].

Looking Ahead: Implications for UK Pharmaceutical Sector

The UK pharmaceutical sector's existing trade agreement provides significant protection from the immediate impact of Trump's 100% tariff threat. However, the three-year duration of the UK-US agreement means companies will need to plan for potential changes when it expires.

Davin Chor, professor and globalisation chair at Dartmouth University's Tuck School of Business, suggests that even if Trump does not end up resurrecting his most aggressive levies, the break in traditional trade patterns will linger. "I don't think you should expect things to go back to business as usual," he said^[3].

The pharmaceutical tariffs may be largely symbolic at this point, as Richard Frank, a senior fellow at the Brookings Institution and director of its Center on Health Policy, noted it was hard to judge the impact of the order^[1]. However, they signal continued pressure on international pharmaceutical companies to establish US manufacturing capabilities or negotiate pricing agreements with the Trump administration.

For UK pharmaceutical companies, the current protection under the December agreement provides breathing room to assess long-term strategies. The sector will need to balance the benefits of maintaining US market access against the costs of increased NHS medicine prices under the current deal, while monitoring whether similar protections will be available after the three-year period expires.